APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sexually Transmitted Diseases (STDs) Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Sexually Transmitted Diseases (STDs) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchSexually Transmitted Diseases (STDs) Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sexually Transmitted Diseases (STDs) Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Sexually Transmitted Diseases (STDs) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sexually Transmitted Diseases (STDs) Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Sexually Transmitted Diseases (STDs) Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Sexually Transmitted Diseases (STDs) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Sexually Transmitted Diseases (STDs) Drug include Bayer Healthcare, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, Hoffmann La Roche, AbbVie, Inc., Pfizer, Eli Lilly and Merck & Co., Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Sexually Transmitted Diseases (STDs) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sexually Transmitted Diseases (STDs) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sexually Transmitted Diseases (STDs) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sexually Transmitted Diseases (STDs) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Sexually Transmitted Diseases (STDs) Drug Segment by Company

Bayer Healthcare

Bristol-Myers Squibb

Gilead Sciences

GlaxoSmithKline Plc

Hoffmann La Roche

AbbVie, Inc.

Pfizer

Eli Lilly

Merck & Co., Inc.

Johnson & Johnson

Sexually Transmitted Diseases (STDs) Drug Segment by Type

Chlamydia

Genital herpes

HPV

Syphilis

Gonorrhea

HIV / AIDS

Sexually Transmitted Diseases (STDs) Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Sexually Transmitted Diseases (STDs) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sexually Transmitted Diseases (STDs) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sexually Transmitted Diseases (STDs) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sexually Transmitted Diseases (STDs) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sexually Transmitted Diseases (STDs) Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Sexually Transmitted Diseases (STDs) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Sexually Transmitted Diseases (STDs) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Sexually Transmitted Diseases (STDs) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Sexually Transmitted Diseases (STDs) Drug Industry Trends Table 2. Sexually Transmitted Diseases (STDs) Drug Industry Drivers Table 3. Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges Table 4. Sexually Transmitted Diseases (STDs) Drug Industry Restraints Table 5. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Sexually Transmitted Diseases (STDs) Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Manufacturers Table 9. Global Sexually Transmitted Diseases (STDs) Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Sexually Transmitted Diseases (STDs) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Sexually Transmitted Diseases (STDs) Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Sexually Transmitted Diseases (STDs) Drug Manufacturers, Product Type & Application Table 13. Global Sexually Transmitted Diseases (STDs) Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Sexually Transmitted Diseases (STDs) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Chlamydia Table 17. Major Manufacturers of Genital herpes Table 18. Major Manufacturers of HPV Table 19. Major Manufacturers of Syphilis Table 20. Major Manufacturers of Gonorrhea Table 21. Major Manufacturers of HIV / AIDS Table 22. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2026) Table 26. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2027-2032) Table 27. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2026) Table 31. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Pharmacies Table 33. Major Manufacturers of Online Pharmacies Table 34. Major Manufacturers of Retail Pharmacies Table 35. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2026) Table 39. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2027-2032) Table 40. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2026) Table 44. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2027-2032) Table 45. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2021-2026) Table 48. Global Sexually Transmitted Diseases (STDs) Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Sexually Transmitted Diseases (STDs) Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2021-2026) Table 66. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2027-2032) Table 67. Bayer Healthcare Company Information Table 68. Bayer Healthcare Business Overview Table 69. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 71. Bayer Healthcare Recent Development Table 72. Bristol-Myers Squibb Company Information Table 73. Bristol-Myers Squibb Business Overview Table 74. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 76. Bristol-Myers Squibb Recent Development Table 77. Gilead Sciences Company Information Table 78. Gilead Sciences Business Overview Table 79. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 81. Gilead Sciences Recent Development Table 82. GlaxoSmithKline Plc Company Information Table 83. GlaxoSmithKline Plc Business Overview Table 84. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 86. GlaxoSmithKline Plc Recent Development Table 87. Hoffmann La Roche Company Information Table 88. Hoffmann La Roche Business Overview Table 89. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 91. Hoffmann La Roche Recent Development Table 92. AbbVie, Inc. Company Information Table 93. AbbVie, Inc. Business Overview Table 94. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 96. AbbVie, Inc. Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 101. Pfizer Recent Development Table 102. Eli Lilly Company Information Table 103. Eli Lilly Business Overview Table 104. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 106. Eli Lilly Recent Development Table 107. Merck & Co., Inc. Company Information Table 108. Merck & Co., Inc. Business Overview Table 109. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 111. Merck & Co., Inc. Recent Development Table 112. Johnson & Johnson Company Information Table 113. Johnson & Johnson Business Overview Table 114. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 116. Johnson & Johnson Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Sexually Transmitted Diseases (STDs) Drug Distributors List Table 120. Sexually Transmitted Diseases (STDs) Drug Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Sexually Transmitted Diseases (STDs) Drug Product Image Figure 2. Global Sexually Transmitted Diseases (STDs) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sexually Transmitted Diseases (STDs) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Sexually Transmitted Diseases (STDs) Drug Sales (2021-2032) & (K Units) Figure 5. Global Sexually Transmitted Diseases (STDs) Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Sexually Transmitted Diseases (STDs) Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Chlamydia Image Figure 9. Genital herpes Image Figure 10. HPV Image Figure 11. Syphilis Image Figure 12. Gonorrhea Image Figure 13. HIV / AIDS Image Figure 14. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2032) Figure 17. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Retail Pharmacies Image Figure 23. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2032) Figure 26. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2021-2032) Figure 43. China Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Sexually Transmitted Diseases (STDs) Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Sexually Transmitted Diseases (STDs) Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Sexually Transmitted Diseases (STDs) Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Chlamydia
  • Genital herpes
  • HPV
  • Syphilis
  • Gonorrhea
  • HIV / AIDS
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline Plc
  • Hoffmann La Roche
  • AbbVie, Inc.
  • Pfizer
  • Eli Lilly
  • Merck & Co., Inc.
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sexually Transmitted Diseases (STDs) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sexually Transmitted Diseases (STDs) Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Sexually Transmitted Diseases (STDs) Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Sexually Transmitted Diseases (STDs) Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Sexually Transmitted Diseases (STDs) Drug Market Dynamics
  1. 2.1 Sexually Transmitted Diseases (STDs) Drug Industry Trends
  2. 2.2 Sexually Transmitted Diseases (STDs) Drug Industry Drivers
  3. 2.3 Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges
  4. 2.4 Sexually Transmitted Diseases (STDs) Drug Industry Restraints
3 Sexually Transmitted Diseases (STDs) Drug Market by Manufacturers
  1. 3.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Sexually Transmitted Diseases (STDs) Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Sexually Transmitted Diseases (STDs) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Sexually Transmitted Diseases (STDs) Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Sexually Transmitted Diseases (STDs) Drug Manufacturers, Product Type & Application
  7. 3.7 Global Sexually Transmitted Diseases (STDs) Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Sexually Transmitted Diseases (STDs) Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Sexually Transmitted Diseases (STDs) Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Sexually Transmitted Diseases (STDs) Drug Tier 1, Tier 2, and Tier 3
4 Sexually Transmitted Diseases (STDs) Drug Market by Type
  1. 4.1 Sexually Transmitted Diseases (STDs) Drug Type Introduction
  2. 4.1.1 Chlamydia
  3. 4.1.2 Genital herpes
  4. 4.1.3 HPV
  5. 4.1.4 Syphilis
  6. 4.1.5 Gonorrhea
  7. 4.1.6 HIV / AIDS
  8. 4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type
  9. 4.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type
  13. 4.3.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2032)
5 Sexually Transmitted Diseases (STDs) Drug Market by Application
  1. 5.1 Sexually Transmitted Diseases (STDs) Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application
  6. 5.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application
  10. 5.3.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2032)
6 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region
  1. 6.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region
  1. 7.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region
  2. 7.1.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032)
  8. 7.2.2 North America Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032)
  11. 7.3.2 Europe Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer Healthcare
  2. 8.1.1 Bayer Healthcare Company Information
  3. 8.1.2 Bayer Healthcare Business Overview
  4. 8.1.3 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  6. 8.1.5 Bayer Healthcare Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 GlaxoSmithKline Plc
  20. 8.4.1 GlaxoSmithKline Plc Company Information
  21. 8.4.2 GlaxoSmithKline Plc Business Overview
  22. 8.4.3 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  24. 8.4.5 GlaxoSmithKline Plc Recent Developments
  25. 8.5 Hoffmann La Roche
  26. 8.5.1 Hoffmann La Roche Company Information
  27. 8.5.2 Hoffmann La Roche Business Overview
  28. 8.5.3 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  30. 8.5.5 Hoffmann La Roche Recent Developments
  31. 8.6 AbbVie, Inc.
  32. 8.6.1 AbbVie, Inc. Company Information
  33. 8.6.2 AbbVie, Inc. Business Overview
  34. 8.6.3 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  36. 8.6.5 AbbVie, Inc. Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Merck & Co., Inc.
  50. 8.9.1 Merck & Co., Inc. Company Information
  51. 8.9.2 Merck & Co., Inc. Business Overview
  52. 8.9.3 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  54. 8.9.5 Merck & Co., Inc. Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Sexually Transmitted Diseases (STDs) Drug Value Chain Analysis
  2. 9.1.1 Sexually Transmitted Diseases (STDs) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Sexually Transmitted Diseases (STDs) Drug Production Mode & Process
  6. 9.2 Sexually Transmitted Diseases (STDs) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Sexually Transmitted Diseases (STDs) Drug Distributors
  9. 9.2.3 Sexually Transmitted Diseases (STDs) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst